

9 October 2019

ASX Announcement

Appendix 3B and Appendix 3Y

Please find attached an Appendix 3B in respect of the issue of 4,677,130 unlisted options issued pursuant to the terms and conditions of the Company's Employee Option Plan.

An Appendix 3Y is also attached in respect of Milan Jerkovic.

The Company also advises of the cancellation of 1,146,651 unlisted employee options expiring 31 December 2021 and 1,157,015 unlisted employee options expiring 30 June 2023.

Blackham Resources Limited

Dan Travers
Company Secretary

For further information on Blackham please contact:

Milan Jerkovic
Executive Chairman
Blackham Resources Limited
Office: +618 9322 6418

Jim Malone
Investor Relations Manager
Blackham Resources Limited
Office: +61 419 537 714

BOARD OF DIRECTORS

Milan Jerkovic - Executive Chairman
Greg Fitzgerald – Non-Executive
Director
Tony James – Non Executive Director

ASX CODE

BLK

CORPORATE INFORMATION

4,407M Ordinary Shares
674M Quoted Options
190M Unquoted Options

PRINCIPAL AND REGISTERED OFFICE

L3 1 Altona Street
West Perth WA 6005

POSTAL ADDRESS

PO Box 1412 West Perth WA 6872

www.blackhamresources.com.au

E: info@blackhamresources.com.au

P: +61 8 9322 6418

F: +61 8 9322 6429

Appendix 3B

New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 01/07/96 Origin: Appendix 5 Amended 01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12, 04/03/13

Name of entity

Blackham Resources Limited

ABN

18 119 887 606

We (the entity) give ASX the following information.

Part 1 - All issues

You must complete the relevant sections (attach sheets if there is not enough space).

- | | | |
|---|---|---|
| 1 | +Class of +securities issued or to be issued | Unlisted options |
| 2 | Number of +securities issued or to be issued (if known) or maximum number which may be issued | 4,677,130 |
| 3 | Principal terms of the +securities (e.g. if options, exercise price and expiry date; if partly paid +securities, the amount outstanding and due dates for payment; if +convertible securities, the conversion price and dates for conversion) | Zero priced options (vesting conditions measured over the 3 year period ended 30 June 2022) expiring 30 June 2023 |

4	Do the ⁺securities rank equally in all respects from the ⁺issue date with an existing ⁺class of quoted ⁺securities? If the additional ⁺securities do not rank equally, please state: - the date from which they do - the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment - the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment	No
5	Issue price or consideration	Issued for nil consideration
6	Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets)	Options issued pursuant to the terms and conditions of the Company's Employee Option Plan and following shareholder approval on 24 September 2019
6a	Is the entity an ⁺eligible entity that has obtained security holder approval under rule 7.1A? If Yes, complete sections 6b – 6h <i>in relation to the ⁺securities the subject of this Appendix 3B</i>, and comply with section 6i	Yes
6b	The date the security holder resolution under rule 7.1A was passed	30 November 2018
6c	Number of ⁺ securities issued without security holder approval under rule 7.1	Nil
6d	Number of ⁺ securities issued with security holder approval under rule 7.1A	Nil
6e	Number of ⁺ securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)	2,522,596 approved by shareholders on 24 September 2019
6f	Number of ⁺ securities issued under an exception in rule 7.2	2,154,534

6g	If +securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the +issue date and both values. Include the source of the VWAP calculation.	N/a														
6h	If +securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements	N/a														
6i	Calculate the entity’s remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements	Refer Annexure 1														
7	+Issue dates Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A. Cross reference: item 33 of Appendix 3B.	9 October 2019														
8	Number and +class of all +securities quoted on ASX (<i>including</i> the +securities in section 2 if applicable)	<table><tr><th>Number</th><th>+Class</th></tr><tr><td>4,407,242,587</td><td>Fully paid ordinary shares</td></tr><tr><td>673,638,562</td><td>Quoted options exercisable at \$0.03 and expiring on 12 October 2020</td></tr></table>	Number	+Class	4,407,242,587	Fully paid ordinary shares	673,638,562	Quoted options exercisable at \$0.03 and expiring on 12 October 2020								
Number	+Class															
4,407,242,587	Fully paid ordinary shares															
673,638,562	Quoted options exercisable at \$0.03 and expiring on 12 October 2020															
9	Number and +class of all +securities not quoted on ASX (<i>including</i> the securities in section 2 if applicable)	<table><tr><th>Number</th><th>+Class</th></tr><tr><td>200,000</td><td>\$0.57 Options expiring on 31 December 2019</td></tr><tr><td>2,000,000</td><td>\$0.308 Options expiring on 29 February 2020</td></tr><tr><td>16,762,108</td><td>ZEPO’s (with vesting conditions measured over a 3 year period ending 31 December 2020) expiring on 31 December 2021</td></tr><tr><td>98,856,260</td><td>ZEPO’s (with vesting conditions measured over a 3 year period ending 30 June 2022) expiring on 30 June 2023</td></tr><tr><td>72,000,000</td><td>Unlisted options exercisable at \$0.08 at any time in the period from 14 February 2019 to 13 February 2024</td></tr></table>	Number	+Class	200,000	\$0.57 Options expiring on 31 December 2019	2,000,000	\$0.308 Options expiring on 29 February 2020	16,762,108	ZEPO’s (with vesting conditions measured over a 3 year period ending 31 December 2020) expiring on 31 December 2021	98,856,260	ZEPO’s (with vesting conditions measured over a 3 year period ending 30 June 2022) expiring on 30 June 2023	72,000,000	Unlisted options exercisable at \$0.08 at any time in the period from 14 February 2019 to 13 February 2024		
Number	+Class															
200,000	\$0.57 Options expiring on 31 December 2019															
2,000,000	\$0.308 Options expiring on 29 February 2020															
16,762,108	ZEPO’s (with vesting conditions measured over a 3 year period ending 31 December 2020) expiring on 31 December 2021															
98,856,260	ZEPO’s (with vesting conditions measured over a 3 year period ending 30 June 2022) expiring on 30 June 2023															
72,000,000	Unlisted options exercisable at \$0.08 at any time in the period from 14 February 2019 to 13 February 2024															

10	Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)	N/A
----	--	-----

Part 2 - Bonus issue or pro rata issue

11	Is security holder approval required?	
12	Is the issue renounceable or non-renounceable?	
13	Ratio in which the +securities will be offered	
14	+Class of +securities to which the offer relates	
15	+Record date to determine entitlements	
16	Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?	
17	Policy for deciding entitlements in relation to fractions	
18	Names of countries in which the entity has +security holders who will not be sent new issue documents Note: Security holders must be told how their entitlements are to be dealt with. Cross reference: rule 7.7.	
19	Closing date for receipt of acceptances or renunciations	
20	Names of any underwriters	
21	Amount of any underwriting fee or commission	
22	Names of any brokers to the issue	
23	Fee or commission payable to the broker to the issue	
24	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of +security holders	
25	If the issue is contingent on +security holders' approval, the date of the meeting	
26	Date entitlement and acceptance form and prospectus or Product Disclosure Statement will be sent to persons entitled	

- | | | |
|----|---|--|
| 27 | If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders | |
| 28 | Date rights trading will begin (if applicable) | |
| 29 | Date rights trading will end (if applicable) | |
| 30 | How do +security holders sell their entitlements <i>in full</i> through a broker? | |
| 31 | How do +security holders sell <i>part of</i> their entitlements through a broker and accept for the balance? | |
| 32 | How do +security holders dispose of their entitlements (except by sale through a broker)? | |
| 33 | +Issue date | |

Part 3 - Quotation of securities

You need only complete this section if you are applying for quotation of securities

- 34 Type of securities
(*tick one*)
- (a) ☐ Securities described in Part 1
- (b) ☐ All other securities
- Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities

Entities that have ticked box 34(a)

Additional securities forming a new class of securities

Tick to indicate you are providing the information or documents

- 35 ☐ If the +securities are +equity securities, the names of the 20 largest holders of the additional +securities, and the number and percentage of additional +securities held by those holders
- 36 ☐ If the +securities are +equity securities, a distribution schedule of the additional +securities setting out the number of holders in the categories
- 1 - 1,000
 - 1,001 - 5,000
 - 5,001 - 10,000
 - 10,001 - 100,000

100,001 and over

- 37 ☐ A copy of any trust deed for the additional ⁺securities

Entities that have ticked box 34(b)

- 38 Number of securities for which ⁺quotation is sought
- 39 Class of ⁺securities for which quotation is sought
- 40 Do the ⁺securities rank equally in all respects from the date of allotment with an existing ⁺class of quoted ⁺securities?
- If the additional securities do not rank equally, please state:
- the date from which they do
 - the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment
 - the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment
- 41 Reason for request for quotation now
- Example: In the case of restricted securities, end of restriction period
- (if issued upon conversion of another security, clearly identify that other security)
- 42 Number and ⁺class of all ⁺securities quoted on ASX (*including* the securities in clause 38)
- | Number | ⁺ Class |
|----------------------|----------------------|
| <input type="text"/> | <input type="text"/> |

Quotation agreement

- 1 ⁺Quotation of our additional ⁺securities is in ASX's absolute discretion. ASX may quote the ⁺securities on any conditions it decides.
- 2 We warrant the following to ASX.
- The issue of the ⁺securities to be quoted complies with the law and is not for an illegal purpose.
 - There is no reason why those ⁺securities should not be granted ⁺quotation.
 - An offer of the ⁺securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any +securities to be quoted and that no-one has any right to return any +securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the +securities be quoted.
 - If we are a trust, we warrant that no person has the right to return the +securities to be quoted under section 1019B of the Corporations Act at the time that we request that the +securities be quoted.
- 3 We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- 4 We give ASX the information and documents required by this form. If any information or document not available now, will give it to ASX before +quotation of the +securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.



Sign here: Date 9 October 2019
(Company Secretary)

Print name: Dan Travers

Appendix 3B – Annexure 1

Calculation of placement capacity under rule 7.1 and rule 7.1A for ⁺eligible entities

Introduced 01/08/12 Amended 04/03/13

Part 1

Rule 7.1 – Issues exceeding 15% of capital	
Step 1: Calculate “A”, the base figure from which the placement capacity is calculated	
Insert number of fully paid ordinary securities on issue 12 months before date of issue or agreement to issue	1,340,911,521
Add the following: - Number of fully paid ordinary securities issued in that 12 month period under an exception in rule 7.2 - Number of fully paid ordinary securities issued in that 12 month period with shareholder approval - Number of partly paid ordinary securities that became fully paid in that 12 month period Note: - Include only ordinary securities here – other classes of equity securities cannot be added - Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed - It may be useful to set out issues of securities on different dates as separate line items	1,609,257 shares issued on exercise of unlisted options (5/12/18) 11,637 shares issued on exercise of quoted options (6/12/18) 27,777,778 shares issued to repay convertible note 15/2/19 – approved by shareholders (30/11/2018) 6,423,474 shares issued pursuant to controlled placement agreement (15/2/19) – approved by shareholders (24/9/19) 1,720,916,438 shares issued pursuant to entitlement issue (15/4/19) 1,567,536 shares issued on exercise of unlisted options (15/4/19) 5,000,000 shares issued to lead manager of entitlement issue (15/4/19) – approved by shareholders (24/9/19) 265,000,000 shares issued pursuant to Mining Services Agreement (20/6/19) – approved by shareholders (24/9/19) 71,428,571 shares issued to repay convertible note 21/6/19 – approved by shareholders (30/11/2018) 107,142,858 shares issued to repay convertible note 10/7/19 – approved by shareholders (30/11/2018) 107,142,857 shares issued to repay convertible note 16/7/19 – approved by shareholders (30/11/2018) 113,657,881 deferred consideration shares (16/7/19) – approved by shareholders (24/9/19) 83,333,334 shares issued to repay convertible note 26/8/19 – approved by shareholders (30/11/2018)

	144,444,445 shares issued to repay convertible note 30/8/19 – approved by shareholders (30/11/2018)
Subtract the number of fully paid ordinary securities cancelled during that 12 month period	Nil
“A”	3,996,367,587

Step 2: Calculate 15% of “A”	
“B”	0.15 <i>[Note: this value cannot be changed]</i>
Multiply “A” by 0.15	599,455,138
Step 3: Calculate “C”, the amount of placement capacity under rule 7.1 that has already been used	
Insert number of equity securities issued or agreed to be issued in that 12 month period <i>not counting</i> those issued: - Under an exception in rule 7.2 - Under rule 7.1A - With security holder approval under rule 7.1 or rule 7.4 Note: <i>This applies to equity securities, unless specifically excluded – not just ordinary securities</i> <i>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</i> <i>It may be useful to set out issues of securities on different dates as separate line items</i>	170,759,875 placement shares (16/9/19)
“C”	170,759,875
Step 4: Subtract “C” from [“A” x “B”] to calculate remaining placement capacity under rule 7.1	
“A” x 0.15 <i>Note: number must be same as shown in Step 2</i>	599,455,138
Subtract “C” <i>Note: number must be same as shown in Step 3</i>	170,759,875
Total [“A” x 0.15] – “C”	428,695,263

Part 2

Rule 7.1A – Additional placement capacity for eligible entities	
Step 1: Calculate “A”, the base figure from which the placement capacity is calculated	
“A” <i>Note: number must be same as shown in Step 1 of Part 1</i>	3,996,367,587
Step 2: Calculate 10% of “A”	
“D”	0.10 <i>Note: this value cannot be changed</i>
Multiply “A” by 0.10	399,636,758
Step 3: Calculate “E”, the amount of placement capacity under rule 7.1A that has already been used	
Insert number of equity securities issued or agreed to be issued in that 12 month period under rule 7.1A <i>Notes:</i> • This applies to equity securities – not just ordinary securities • Include here – if applicable – the securities the subject of the Appendix 3B to which this form is annexed • Do not include equity securities issued under rule 7.1 (they must be dealt with in Part 1), or for which specific security holder approval has been obtained • It may be useful to set out issues of securities on different dates as separate line items	240,115,125 placement shares (16/9/19)
“E”	240,115,125
Step 4: Subtract “E” from [“A” x “D”] to calculate remaining placement capacity under rule 7.1A	
“A” x 0.10 <i>Note: number must be same as shown in Step 2</i>	399,636,758
Subtract “E” <i>Note: number must be same as shown in Step 3</i>	240,115,125
Total [“A” x 0.10] – “E”	159,521,633 <i>Note: this is the remaining placement capacity under rule 7.1A</i>

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.

Name of entity	BLACKHAM RESOURCES LIMITED
ABN	18 119 887 606

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Milan Jerkovic
Date of last notice	16 April 2019

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct and Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	1. Xavier Group P/L (Mr Jerkovic is a director) 2. Sam Investors Pty Ltd (The Milenda A/C) (Mr Jerkovic is a director)
Date of change	9 October 2019

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

No. of securities held prior to change	Direct 64,263,256 fully paid ordinary shares. 2,500,000 unquoted Zero Exercise Price Options ("ZEPOs") with a \$nil exercise price, and an expiry date of 31/12/2021. 19,243,071 quoted options exercisable at \$0.03 on or before 12/10/2020 Indirect 1. ▪ 7,616,765 fully paid ordinary shares. ▪ 1,410,512 quoted options exercisable at \$0.03 on or before 12/10/2020 2. ▪ 1,338,750 fully paid ordinary shares. ▪ 247,916 quoted options exercisable at \$0.03 on or before 12/10/2020
Class	Unquoted Zero Exercise Price Options ("ZEPOs") with a \$nil exercise price, and an expiry date of 30/6/2023.
Number acquired	2,522,596
Number disposed	Nil
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	Issued for nil consideration

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

No. of securities held after change	Direct 64,263,256 fully paid ordinary shares. 2,500,000 unquoted Zero Exercise Price Options ("ZEPOs") with a \$nil exercise price, and an expiry date of 31/12/2021. 2,522,596 unquoted Zero Exercise Price Options ("ZEPOs") with a \$nil exercise price, and an expiry date of 30/6/2023. 19,243,071 quoted options exercisable at \$0.03 on or before 12/10/2020 Indirect 1. ▪ 7,616,765 fully paid ordinary shares. ▪ 1,410,512 quoted options exercisable at \$0.03 on or before 12/10/2020 2. ▪ 1,338,750 fully paid ordinary shares. ▪ 247,916 quoted options exercisable at \$0.03 on or before 12/10/2020
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Options issued pursuant to shareholder approval on 24 September 2019 and the terms and conditions of the Company's Employee Options Plan.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/a
Nature of interest	N/a
Name of registered holder (if issued securities)	N/a
Date of change	N/a
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/a
Interest acquired	N/a
Interest disposed	N/a
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/a

+ See chapter 19 for defined terms.

Interest after change	N/a
------------------------------	-----

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/a
If prior written clearance was provided, on what date was this provided?	N/a

⁺ See chapter 19 for defined terms.